Gemcitabine: a phase II study in patients with advanced renal cancer

Cancer Chemotherapy and Pharmacology
P H De MulderJ Blatter

Abstract

Gemcitabine is a fluorine-substituted cytarabine analog with broad experimental antitumor activity. It's activity was explored in chemotherapy-naive patients with advanced progressive renal-cell carcinoma. A total of 39 patients were included in the study, of whom 37 were fully evaluable. In five patients the primary tumor remained in situ. Gemcitabine at 800 mg/m2 was given as a weekly 30-min infusion for 3 consecutive weeks followed by 1 week of rest. One complete response and two partial responses were observed giving a response rate of 8.1% [95% confidence interval (CI), 2-22%]. The duration of the responses is currently 32, 15, and 19 months, respectively. The median survival for all patients was 12.3 months. Gemacitabine was generally well tolerated, with nausea and vomiting (20.5% grade III) and neutropenia (5.3% grade III) being the most significant side effects. Gemcitabine given at this dose level and on this schedule has only limited activity in advanced renal-cell carcinoma.

References

Mar 1, 1977·The Journal of Urology·J E MontieD K Montague
Jan 1, 1988·Seminars in Surgical Oncology·A de ForgesJ P Droz
Apr 1, 1993·Annals of Oncology : Official Journal of the European Society for Medical Oncology·W C MertensD Wong

❮ Previous
Next ❯

Citations

Feb 17, 2010·Cancer Chemotherapy and Pharmacology·Seiji NaitoHideyuki Akaza
Feb 24, 2005·World Journal of Urology·Wolfgang Lilleby, Sophie D Fosså
Jul 4, 2001·Gastroenterology Clinics of North America·S H Sial, M F Catalano
Jul 10, 2003·Critical Reviews in Oncology/hematology·Cora N Sternberg, Nicholas J Vogelzang
May 6, 2008·Anti-cancer Drugs·Yoshiro FujiwaraMitsune Tanimoto
Jun 3, 2009·American Journal of Clinical Oncology·Peter J Van VeldhuizenDavid E Crawford
Nov 14, 2013·Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire·Vijaya L DamarajuMichael B Sawyer
Dec 16, 1998·Lancet·N J Vogelzang, W M Stadler
Aug 1, 1997·Aging : Clinical and Experimental Research·C MartinR Rosso
Sep 1, 2015·Critical Reviews in Oncology/hematology·E DiamondD M Nanus
May 10, 2005·BJU International·Michael StaehlerMichael Siebels
May 10, 2007·Clinical Transplantation·Tak YunKyoo-Hyung Lee
Sep 3, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Ulrich KeilholzEckhard Thiel
Jan 27, 2000·The Journal of Urology·R J Motzer, P Russo
Nov 3, 2005·Expert Opinion on Emerging Drugs·Philip E Shaheen, Ronald M Bukowski
Apr 3, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Emmanuel I PapadopoulosAndreas Scorilas
Oct 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John D HainsworthAnthony Greco
Jun 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B I RiniW M Stadler

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.